Quantifying SARS-CoV-2 and Ebola Pseudotype Infectivity
Corresponding Organization :
Other organizations : Hokkaido University, National Institutes of Health, National Institute of Allergy and Infectious Diseases, National Hospital Organization Hokkaido Medical Center
Variable analysis
- Strain of SARS-CoV-2 used (JPN/TY/WK-521)
- Cell line used for virus propagation (Vero-TMPRSS2 cells)
- Cell culture medium composition (2%-FBS/DMEM)
- Temperature and CO2 conditions (37°C, 5% CO2)
- Pseudotyped VSVs used (VSV-SARS2 and VSV-EBOV)
- Pretreatment of pseudotyped VSVs with neutralizing MAb to VSV G
- Infectious titers of SARS-CoV-2 determined by TCID50 assays
- Infectious units (IU) of pseudotyped VSVs determined by counting GFP-expressing cells
- Vero-TMPRSS2 cell line used for both virus propagation and TCID50 assays
- Incubation time for pseudotyped VSV inoculation (20 h)
- Positive control: Parental VSV
- Negative control: Pretreated pseudotyped VSVs to abolish background infectivity of parental VSV
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!